PARIS (Reuters) – Biomrieux, a French healthcare company specialising in diagnostics, said on Monday it had won more positive feedback from the U.S. Food & Drug Administration (FDA) regulator for its product aimed at helping test for the coronavirus.
BioMerieux’s shares rose 3 percent in early session trading.
BioMerieux said its ‘BIOFIRE RP2.1′ panel testing product, which includes 22 pathogens that cause respiratory infections including SARS-CoV-2 which causes the COVID-19 coronavirus, had won ’emergency use authorisation’ from the FDA.
While the ‘BIOFIRE RP2.1′ test has not had full clearance or approval from the FDA, the decision to give the product ’emergency use authorisation’ nevertheless marks more progress.
BioMrieux said it was looking to scale up supply of the BIOFIRE RP2.1 panel at its production facilities in Salt Lake City (Utah, USA).
Test kits will be available for commercial distribution in the USA under the emergency use authorisation, as well as internationally where regulatory approval allows.
BioMrieux added it expected to steadily build inventory levels to address the needs of the thousands of labs and healthcare professionals given an expected rise in demand for products aimed at testing for the presence of the coronavirus.
(Reporting by Sudip Kar-Gupta; Editing by Kim Coghill)
